Vagus Stimulation in Female Long COVID Patients. — Vagus  

Long COVID Clinical Trial

Official title: Effects of Transcutaneous Electrical Neurostimulation on Female Patients With Long COVID - a Pilot Study

Status Recruiting

Clinical Trial Summary

The aim of the present pilot study is to investigate the acceptance, feasibility and implementation of the vagus nerv stimulation in Long COVID patients. Additionally, the effects on parameters of the autonomic nervous system as well as on symptoms of Long COVID will be described in a pre/post comparison.

For this purpose, a total of 45 female Long COVID patients will participate in the randomized controlled pilot study. Patients will perform auricular vagus stimulation daily for 12 weeks. The patient collective will be randomized into three groups (A: 10 hertz, B: 25 hertz, C: 2 hertz=control group).

If appropriate results are obtained, further adequately powered intervention studies are planned.

Clinical Trial Description

Patients start on day 0, when the first assessment takes place. This consists of a medical diagnostic interview and sociodemographic, anthropometric, medical and functional data are collected (for a detailed description, see chapter 5. Statistics). Subsequently, the patients fill out the given questionnaires (paper/pencil version), which are then evaluated. Subsequently, the test persons are trained by a doctor how the electrical stimulation works with a demo device. Finally, the device is taken over by the company Schwa-Medico. The whole first assessment lasts about 2 hours and always takes place from 8 a.m. at constant room temperature (22-23 C°).

The outcome parameters are recorded before the start of the vagus nerve stimulation (T0), during the treatment after 4 weeks (T0+4Wo) and after a total of 12 weeks (T0+12Wo) after the end of the therapy. Which assessments are collected at the different time points is listed in the biometry section. The assessments are performed by physicians of the Department of Physical Medicine, Rehabilitation and Occupational Medicine. All assessments take place at relatively the same time, at constant room temperature (22-23 C°). The patients have to appear fasting.

T0: Medical history, examination, randomization, pre-tests, enrollment. T0+4Wo: Intermediate examination T0+12Wo: final examination, post-tests, return of device

This pilot study investigates the acceptability, feasibility, and implementation of the VNS measure in Long COVID patients. In addition, effects on autonomic nervous system parameters (heart rate, blood pressure, rate pressure product, heart rate variability = HRV, cortisol in saliva), on symptoms fatigue, dyspnea as well as health-related quality of life (HRQOL) are described:

Time points: T0, T0+4wk, T0+12wk.

Parameters - collected at relatively the same time each day, at constant room temperature (22-23 C°):

• Documentation of blood pressure and pulse rate: by means of Boso Medicus (Bosch + Sohn GmbH u. Co. KG, Jungingen, Germany), calculation of the so-called "rate pressure-product" (syst. blood pressure x heart rate)

• Heart rate variability

• Salivary cortisol

• Fatigue: Brief Fatigue Inventory (BFI)

• Health-related quality of life (HRQOL): SF-36 (short form) questionnaire instrument

• Dyspnea: Modified Borg Scale

• Sleep: Insomnia Severity Index (ISI) ;

Related Conditions & MeSH terms

• COVID-19
• Disease
• Long COVID
• Nervous System Diseases
• Post-COVID-19 Syndrome
• Syndrome
• Vagus Nerve Diseases

• NCT number: NCT05918965
• Study type: Interventional
• Source: Medical University of Vienna
• Contact: Veronika Helbich-Poschacher, M.D.
• Phone: +4314040043300
• Email: veronika.helbich-poschacher@meduniwien.ac.at
• Status: Recruiting
• Phase: N/A
• Start date: March 22, 2023
• Completion date: March 1, 2025